4-[(2-甲基-4-喹啉)甲氧基]苯胺 | 654647-30-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-[(2-甲基-4-喹啉)甲氧基]苯胺
• 英文名称: 4-[(2-methyl-4-quinolinyl)methoxy]aniline
• 英文别名: 4-(2-methyl-4-quinolylmethyloxy)aniline；4-((2-methylquinolin-4-yl)methoxy)aniline；4-(2-methylquinolin-4-methyloxy)aniline；4-[(2-methylquinolin-4-yl)methoxy]aniline
• CAS: 654647-30-0
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.327
• InChiKey: CCRBEQBUUQLUEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(2-甲基-4-喹啉)甲氧基]苯胺 在 三乙酰氧基硼氢化钠 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S,3S)-1-Methyl-2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenylcarbamoyl]-piperidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization

  摘要：

  Modifications of the lead TACE inhibitor 1 (N-hydroxy-trans-2-{[4-(4-quinolinyloxymethyl)anilinyl]carbonyl}-1-cyclo-hexanecarboxamide) at the cyclohexyl ring and the quinoline moiety led to the identification of a series of piperidine containing TACE inhibitors with potent activity in the inhibition of TNF-alpha release in the whole blood assay (WBA). The most potent analogue IM491 [N-hydroxy-(5S,6S)-1-methyl-6-{[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl}-5-piperidinecarboxamide] exhibited an IC50 value of 20 nM in WBA with excellent selectivity over MMP-1, -2 and -9 and is orally bioavailable with an F value of 43% in beagle dogs. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.057
• 作为产物：
  描述：

  4-(BOC-氨基)酚 在 potassium carbonate 作用下， 生成 4-[(2-甲基-4-喹啉)甲氧基]苯胺
  参考文献：
  名称：

  Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization

  摘要：

  Modifications of the lead TACE inhibitor 1 (N-hydroxy-trans-2-{[4-(4-quinolinyloxymethyl)anilinyl]carbonyl}-1-cyclo-hexanecarboxamide) at the cyclohexyl ring and the quinoline moiety led to the identification of a series of piperidine containing TACE inhibitors with potent activity in the inhibition of TNF-alpha release in the whole blood assay (WBA). The most potent analogue IM491 [N-hydroxy-(5S,6S)-1-methyl-6-{[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl}-5-piperidinecarboxamide] exhibited an IC50 value of 20 nM in WBA with excellent selectivity over MMP-1, -2 and -9 and is orally bioavailable with an F value of 43% in beagle dogs. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.057

文献信息

• Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030130273A1

  公开（公告）日：2003-07-10

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 11 , and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了具有以下式(I)的新型咪唑啉衍生物：1或其药用可接受的盐或前药形式，其中A、B、R1、R2、R3、R4、R5、R6、R7、R11和n在本说明书中有定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶的抑制剂，或其组合。
• [EN] SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS<br/>[FR] DERIVES DE SULPHONAMIDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE TACE
  申请人：ASTRAZENECA AB

  公开号：WO2004024715A1

  公开（公告）日：2004-03-25

  Sulphonamide derivatives that are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α Converting Enzyme (TACE).

  对金属蛋白酶抑制和特别是对TNF-α转化酶（TACE）抑制有用的磺胺衍生物。
• [EN] SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE D'HYDROXAMATES CYCLIQUES SUBSTITUES
  申请人：INCYTE CORP

  公开号：WO2005037826A1

  公开（公告）日：2005-04-28

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式I的化合物：其对映异构体，二对映异构体，混合物，前药，结晶形式，非晶形式，无定形形式，溶剂化物，代谢物和药学上可接受的盐，其中环A取代基在以下披露中被完全定义。公式I的化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要MMPs抑制的疾病中有用。
• [EN] HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] DERIVES D'HYDANTOINE UTILISES COMME INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002096426A1

  公开（公告）日：2002-12-05

  The present application describes novel hydantoin derivatives of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R?1, R2, R3, R4, R5, R6, R7, R11¿, and n are defined in the present specification, which are useful as inhibitors of matrix metallproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式（I）的新型脲嘧啶衍生物，或其药学上可接受的盐或前药形式，其中A，B，R？1，R2，R3，R4，R5，R6，R7，R11¿和n在本说明书中有定义，它们可用作基质金属蛋白酶（MMP），TNF-α转化酶（TACE），聚集素酶或其组合的抑制剂。
• Sulphonamide derivatives and their use as tace inhibitors
  申请人：Burrows Nicholas Jeremy

  公开号：US20050256176A1

  公开（公告）日：2005-11-17

  Sulphonamide derivatives that are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α Converting Enzyme (TACE).

  磺酰胺衍生物在抑制金属蛋白酶中是有用的，尤其是在抑制TNF-α转化酶（TACE）方面。